SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
Status:
Terminated
Trial end date:
2018-08-23
Target enrollment:
Participant gender:
Summary
This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC)
or large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC)
comprised of a monoclonal antibody linked to a potent chemotherapy.
The purpose of this study is to assess the safety and tolerability of SC-002 at different
dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC
or LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of
SC-002.